Literature DB >> 19053758

Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding characterization at D2/D3 receptors and elucidation of a pharmacophore model.

Dennis A Brown1, Prashant S Kharkar, Ingrid Parrington, Maarten E A Reith, Aloke K Dutta.   

Abstract

A series of structurally constrained analogues based on hybrid compounds containing octahydrobenzo[g or f]quinoline moieties were designed, synthesized, and characterized for their binding to dopamine D2 and D3 receptors expressed in HEK-293 cells. Among the newly developed constrained molecules, trans-octahydrobenzo[f]quinolin-7-ol (8) exhibited the highest affinity for D2 and D3 receptors, the (-)-isomer being the eutomer. Interestingly, this hybrid constrained version 8 showed significant affinity over the corresponding nonhybrid version 1 (representing a constrained version of the aminotetralin structure only) when assayed under same conditions (K(i) of 49.1 and 14.9 nM for 8 vs 380 and 96.0 nM for 1 at D2 and D3, respectively). Similar results were found with other lead hybrid compounds, indicating a contribution of the piperazine moiety in the observed enhanced affinity. On the basis of the data of new lead constrained derivatives and other lead hybrid derivatives developed by us, a unique pharmacophore model was proposed consisting of three pharmacophoric centers, two with aromatic/hydrophobic and one with cationic features.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19053758      PMCID: PMC2607046          DOI: 10.1021/jm8008629

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  26 in total

Review 1.  Dopamine receptors--physiological understanding to therapeutic intervention potential.

Authors:  G Emilien; J M Maloteaux; M Geurts; K Hoogenberg; S Cragg
Journal:  Pharmacol Ther       Date:  1999-11       Impact factor: 12.310

2.  Synthesis and pharmacology of some 2-aminotetralins. Dopamine receptor agonists.

Authors:  J D McDermed; G M McKenzie; A P Phillips
Journal:  J Med Chem       Date:  1975-04       Impact factor: 7.446

3.  Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach.

Authors:  Judith Varady; Xihan Wu; Xueliang Fang; Ji Min; Zengjian Hu; Beth Levant; Shaomeng Wang
Journal:  J Med Chem       Date:  2003-10-09       Impact factor: 7.446

4.  Synthesis and dopaminergic activity of (+/-)-, (+)-, and (-)-2-dipropylamino-5-hydroxy-1,2,3,4-tetrahydronaphthalene.

Authors:  J D McDermed; G M McKenzie; H S Freeman
Journal:  J Med Chem       Date:  1976-04       Impact factor: 7.446

5.  The conformation of dopamine at its receptor: binding of monohydroxy-2-aminotetralin enantiomers and positional isomers.

Authors:  J L Tedesco; P Seeman; J D McDermed
Journal:  Mol Pharmacol       Date:  1979-09       Impact factor: 4.436

6.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

7.  N-Alkylated 2-aminotetralins: central dopamine-receptor stimulating activity.

Authors:  U Hacksell; U Svensson; J L Nilsson; S Hjorth; A Carlsson; H Wikström; P Lindenberg; D Sanchez
Journal:  J Med Chem       Date:  1979-12       Impact factor: 7.446

8.  The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors.

Authors:  J M Witkin; B Levant; A Zapata; R Kaminski; M Gasior
Journal:  J Pharmacol Exp Ther       Date:  2008-06-19       Impact factor: 4.030

9.  Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors.

Authors:  Aloke K Dutta; Sylesh K Venkataraman; Xiang-Shu Fei; Rohit Kolhatkar; Shijun Zhang; Maarten E A Reith
Journal:  Bioorg Med Chem       Date:  2004-08-15       Impact factor: 3.641

10.  Cerebral dopamine agonist properties of some 2-aminotetralin derivatives after peripheral and intracerebral administration.

Authors:  J G Cannon; T Lee; H D Goldman
Journal:  J Med Chem       Date:  1977-09       Impact factor: 7.446

View more
  9 in total

Review 1.  Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

Authors:  Amy E Moritz; R Benjamin Free; David R Sibley
Journal:  Cell Signal       Date:  2017-07-14       Impact factor: 4.315

2.  High-affinity and selective dopamine D₃ receptor full agonists.

Authors:  Jianyong Chen; Beth Levant; Shaomeng Wang
Journal:  Bioorg Med Chem Lett       Date:  2012-07-11       Impact factor: 2.823

3.  Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors.

Authors:  Bhaskar Gopishetty; Suhong Zhang; Prashant S Kharkar; Tamara Antonio; Maarten Reith; Aloke K Dutta
Journal:  Bioorg Med Chem       Date:  2013-04-01       Impact factor: 3.641

Review 4.  Revision of the classical dopamine D2 agonist pharmacophore based on an integrated medicinal chemistry, homology modelling and computational docking approach.

Authors:  N Krogsgaard-Larsen; K Harpsøe; J Kehler; C T Christoffersen; P Brøsen; T Balle
Journal:  Neurochem Res       Date:  2014-07-24       Impact factor: 3.996

Review 5.  Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.

Authors:  Christian A Heidbreder; Amy H Newman
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

6.  Interaction of novel hybrid compounds with the D3 dopamine receptor: Site-directed mutagenesis and homology modeling studies.

Authors:  Sandhya Kortagere; Shu-Yuan Cheng; Tamara Antonio; Juan Zhen; Maarten E A Reith; Aloke K Dutta
Journal:  Biochem Pharmacol       Date:  2010-09-15       Impact factor: 5.858

7.  Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.

Authors:  Balaram Ghosh; Tamara Antonio; Bhaskar Gopishetty; Maarten Reith; Aloke Dutta
Journal:  Bioorg Med Chem       Date:  2010-06-12       Impact factor: 3.641

8.  Understanding the Structural Requirements of Hybrid (S)-6-((2-(4-Phenylpiperazin-1-yl)ethyl)(propyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol and its Analogs as D2/D3 Receptor Ligands: A Three-Dimensional Quantitative Structure-Activity Relationship (3D QSAR) Investigation.

Authors:  Gyan Modi; Horrick Sharma; Prashant S Kharkar; Aloke K Dutta
Journal:  Medchemcomm       Date:  2014-09-01       Impact factor: 3.597

9.  Evaluation of 1,2-Benzothiazine 1,1-dioxide Derivatives In Vitro Activity towards Clinical-Relevant Microorganisms and Fibroblasts.

Authors:  Ruth K Dudek-Wicher; Berenika M Szczęśniak-Sięga; Rafał J Wiglusz; Jan Janczak; Marzenna Bartoszewicz; Adam F Junka
Journal:  Molecules       Date:  2020-07-31       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.